WO2019166418A1 - Composition nutraceutique ou pharmaceutique - Google Patents

Composition nutraceutique ou pharmaceutique Download PDF

Info

Publication number
WO2019166418A1
WO2019166418A1 PCT/EP2019/054701 EP2019054701W WO2019166418A1 WO 2019166418 A1 WO2019166418 A1 WO 2019166418A1 EP 2019054701 W EP2019054701 W EP 2019054701W WO 2019166418 A1 WO2019166418 A1 WO 2019166418A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
composition according
collagen hydrolyzate
collagen
nutraceutical
Prior art date
Application number
PCT/EP2019/054701
Other languages
German (de)
English (en)
Inventor
Steffen Oesser
Stephan Hausmanns
Hans-Ulrich Frech
Original Assignee
Gelita Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gelita Ag filed Critical Gelita Ag
Publication of WO2019166418A1 publication Critical patent/WO2019166418A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A23L33/28—Substances of animal origin, e.g. gelatin or collagen
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/142—Amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/163—Sugars; Polysaccharides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A23L2/66—Proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
    • A23L29/275—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of animal origin, e.g. chitin
    • A23L29/281—Proteins, e.g. gelatin or collagen
    • A23L29/284—Gelatin; Collagen
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0216—Solid or semisolid forms
    • A61K8/022—Powders; Compacted Powders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/042—Gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/92—Oral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines

Definitions

  • the present invention relates to a nutraceutical or pharmaceutical composition for use in improving endurance performance.
  • the invention further relates to a nutraceutical or pharmaceutical composition for use in stimulating fat loss, in particular for reducing body weight.
  • a high-carbohydrate diet is beneficial, and especially preferable to a high-fat diet.
  • the essential muscle energy reserve namely the glycogen content in the muscle cells, can be replenished to a normal level within 24 hours with a high carbohydrate intake of 7 to 10 g per kg of body mass per day (see eg A. Jeukendrup, Schweizerische Zeitschrift für Sports Medicine and Sports Traumatology 2003 (51) 17-23).
  • optimal levels of glycogen delay the onset of fatigue, extend the duration of an equilibrium load by approximately 20%, and improve performance by 2 to 3% at a defined distance or work to be handled.
  • the object of the present invention is to propose a nutraceutical or pharmaceutical composition with which the endurance capacity can be additionally increased, i. by an effect beyond the replenishment of glycogen reserves.
  • compositions for use in improving endurance performance wherein the composition comprises one or more carbohydrates and collagen hydrolyzate.
  • compositions for use in stimulating fat loss, in particular for reducing body weight which composition comprises one or more carbohydrates and collagen hydrolyzate.
  • collagen hydrolyzate results in an increase in mitochondrial activity in human and animal cells, i. an increase in the mitochondrial count per cell and / or an enlargement of the individual mitochondria. From this finding, it is found that collagen hydrolyzate can be advantageously combined with carbohydrates to produce nutraceutical or pharmaceutical compositions for specifically enhancing endurance performance and stimulating fat breakdown by increasing mitochondrial activity in the muscle cells.
  • Collagen hydrolyzate which is produced in particular by the enzymatic hydrolysis of collagen-containing animal starting materials, consists of a mixture of peptides whose molecular weights are distributed over a certain size range depending on the starting material and production conditions.
  • the use of collagen hydrolyzate as a dietary supplement has been known for a long time, in particular for the prevention and / or treatment of disorders associated with the bone, joints or connective tissue, in particular a stimulating effect of the collagen peptides on the synthesis the body's own extracellular matrix could be shown in these tissue types (see, eg, Bel Io et al., Curr. Med. Res. Opin. 2006 (22) 2221-2232).
  • the endurance capacity of the human or animal body correlates with the capacity of the aerobic metabolism to supply the muscles with the required energy in the form of ATP (adenosine triphosphate) over a longer period of time.
  • Critical to the aerobic capacity is the oxygen uptake, which in turn is determined by three factors: oxygen supply via the lungs, oxygen transport via the cardiovascular system and oxygen utilization in the muscle cells.
  • the oxygen transport and the oxygen utilization can be increased by training and other measures, whereby the final step is usually the decisive, limiting factor , Endurance capacity therefore depends essentially on the number of mitochondria (per muscle cell or in the total muscle) in which the oxygen-consuming and ATP-generating reactions of the respiratory chain take place.
  • an increase in mitochondrial activity means that the body's basal metabolic rate increases and a higher amount of nutrients are metabolized per unit of time for energy. These nutrients are provided at least partially in the form of the carbohydrates contained in the composition according to the invention.
  • the ingredients of the composition thus complement each other optimally to improve endurance performance in accordance with the first aspect of the invention.
  • the invention relates to nutraceutical compositions intended for non-therapeutic use, ie, administration of the collagen hydrolyzate to persons or animals that are not in need of therapy in the medical sense in terms of endurance performance or body weight. Rather, the use is on the one hand with the aim of a generally desirable increase in Enduranceperformance.
  • composition of the invention in animals may be useful, for example, for horses, dogs or camels, especially in animal racing.
  • the invention also includes pharmaceutical compositions intended for therapeutic use, i. for the prevention and / or treatment of a pathological condition characterized by a reduction in mitochondrial activity.
  • a pathological condition characterized by a reduction in mitochondrial activity.
  • the pathological condition can be characterized by a reduced endurance capacity and / or by an increased body weight.
  • the pathological condition is preferably selected from adiposity, cardiovascular diseases, cardiac arrhythmias, cardiac insufficiency, hypotension, hypertension, metabolic disorders, diabetes mellitus, metabolic syndrome, sideroblastic anemia, functional disorders of the kidney and the liver, Neuropathy, ataxia, epileptic seizures, dementia, Alzheimer's disease, autism, depression, chronic fatigue syndrome, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, stroke-like symptoms, migraine, myoclonic, paralysis, neuralgia, hyperpathia, hyperesthesia, dysphagia disorders, vomiting, constipation, diarrhea, degeneration of optic nerve fibers and the retina, impaired eye movement, ptosis, night blindness, obesity, deafness and inner ear disorders.
  • adiposity cardiovascular diseases, cardiac arrhythmias, cardiac insufficiency, hypotension, hypertension, metabolic disorders, diabetes mellitus, metabolic syndrome, sideroblastic anemia, functional disorders of the kidney and the liver, Neuro
  • collagen hydrolyzate leads to increased expression of the enzyme AMP-activated protein kinase (AMPK).
  • AMPK AMP-activated protein kinase
  • This regulatory enzyme also affects the energy metabolism of the cell, so that an increase in the AMPK amount has a positive effect on endurance performance and fat loss.
  • composition of the invention is preferably for enteral administration, especially for oral administration.
  • nutraceutical composition it is preferably a food or a dietary supplement, depending on how high the carbohydrate content is and what intake level of the composition is provided.
  • a nutraceutical composition it is particularly advantageous to administer in the form of a solution, e.g. in the form of finished ampoules, a powder or a gel, or in the form of tablets. Due to its good solubility, collagen hydrolyzate can also be added to various drinks without causing turbidity. The use of taste-neutral collagen hydrolyzate can increase user acceptance.
  • the composition according to the invention may contain the collagen hydrolyzate and the carbohydrate (s) in very different weight ratios.
  • the weight ratio of collagen hydrolyzate to carbohydrate (s) ranges from 1:20 to 10: 1, preferably from 1:10 to 5: 1, more preferably from 1: 5 to 3: 1, even more preferably from 1: 3 up to 2: 1, in particular from 1: 2 to 2: 1.5.
  • compositions with a high proportion of carbohydrates are intended in particular to be administered in larger quantities, so that a considerable part of the energy requirement is covered thereby, whereas compositions with a higher proportion of collagen hydrolyzate are more suitable than typical dietary supplements, by the other energy supply is only increased.
  • the intended administration of the composition according to the invention may thus advantageously be from 0.1 to 5 g per kg body weight per day, preferably from 0.5 to 1.5 g per kg body mass.
  • a carbohydrate-rich diet can thus be realized, in which the composition according to the invention makes up a substantial portion of the total carbohydrates supplied.
  • This variant can e.g. be sensible for competitive athletes as part of a special diet.
  • the mixing ratio in the composition and the amount to be administered are desirably coordinated so that the composition is administered with an amount of collagen hydrolyzate of from 1 to 40 g per day, preferably from 2.5 to 25 g per day preferably from 5 to 20 g per day, and especially from 10 to 15 g per day.
  • the carbohydrate (s) in the composition according to the invention may be selected from monosaccharides, disaccharides and polysaccharides, preferably from glucose, fructose, sucrose, trehalose, isomaltulose, lactose, starch and mixtures thereof, more preferably from the glycemic carbohydrates glucose, fructose and sucrose. Particularly favorable is a glucose / fructose mixture in the ratio of about 2: 1.
  • the composition contains no further proteins, protein hydrolysates or amino acids in addition to the collagen hydrolyzate.
  • proteins are used in known food supplements for muscle building and muscle maintenance, in particular especially in athletes, with the aim of replacing carbohydrates and fats as energy suppliers to a large extent by proteins.
  • the composition according to the invention is not based on the function of collagen hydrolyzate as an energy source, but on its specific effect on mitochondrial activity as described above. This supplements the effect of the carbohydrate (s) as an energy source to replenish the muscular glycogen stores.
  • the composition in addition to the collagen hydrolyzate and the carbohydrate (s), the composition contains no other physiologically active ingredients.
  • the invention also encompasses the case in which the collagen hydrolyzate and the carbohydrate or carbohydrates are administered as constituents of a foodstuff with various further constituents.
  • the nutraceutical compositions according to the invention may be chocolate bars, protein bars or cereal bars, or rubber or pastry products (so-called functional foods), or drinks (eg isonic drinks or energy drinks), milk products (eg milkshakes , Jog-hurt) or milk substitutes (eg soymilk, almond milk and coconut milk).
  • the collagen hydrolyzate and the carbohydrate or carbohydrates are combined with water and electrolytes, in particular in the form of an isotonic solution.
  • a composition is particularly advantageous as a drink for athletes to simultaneously allow effective rehydration.
  • composition according to the invention comprises, in addition to the collagen hydrolyzate and the carbohydrate or carbohydrates, further physiologically active constituents, these are preferably one or more components which have a positive effect on the general health and in particular on endurance performance.
  • components are preferably selected from vitamin C, vitamins of the B, D, E and K series, conjugated linoleic acids, caffeine and its derivatives, guarana extract, green tea extract, beetroot extract, lemon verbena extract, orange peel, epigallocatechin gallate, epicatechins from cocoa, creatine including its derivatives, L-carnitine, L-citrulline, L-arginine, nitric oxide, nitrates, amino acids including branched chain amino acids, omega-3 and omega-6 fatty acids, lipoic acids including ⁇ -lipoic acid, N-acetylcysteine, NADH, D-ribose, magnesium aspartate, antioxidants such as anthocyanins, Polyphenols, carotenoids, fla
  • the composition further comprises ubiquinone-10 and / or ubiquinol, ie the oxidized or reduced form of the coenzyme Qi 0 , with ubiquinol being preferred because of its better bioavailability.
  • ubiquinol being preferred because of its better bioavailability.
  • a daily intake of 50 to 100 mg ubiquinol a positive effect on the physical performance was observed, whereby a promotion of mitochondrial activity is assumed by the antioxidant effect of ubiquinol.
  • the effect of the collagen hydrolyzate in the above-mentioned indications associated with mitochondrial dysfunction can be promoted in this way.
  • a combination with pyrroloquinoline quinone (PQQ) is possible, which has recently been discovered as an important redox cofactor.
  • the administration of the composition is provided in combination with endurance training or altitude training.
  • Endurance training can increase the aerobic capacity of the metabolism.
  • a physical training under relative hypoxia hyperoxia training
  • hyperxia training has a strong effect on the endurance performance, so that when given at the same time of collagen hydrolyzate is to assume in each case of a synergistic effect. This is of particular interest to athletes.
  • the molecular weight of the collagen hydrolyzate contained in the composition can vary over a wide range according to the invention, with an upper limit being that, unlike denatured collagen or gelatin, collagen hydrolyzate has a sufficiently high degree of hydrolysis to be water-soluble at room temperature and not to gel.
  • the soluble peptides of the collagen hydrolyzate can be well absorbed in the body.
  • the collagen hydrolyzate has an average molecular weight of from 200 to 25,000 Da, preferably from 1,000 to 15,000 Da, more preferably from 1,200 to 12,000 Da, even more preferably from 1,500 to 8,000 Da, and most preferably from 1,800 to 5,500 Da.
  • the collagen hydrolyzate is conveniently prepared by enzymatic hydrolysis of a collagen-containing starting material.
  • endopeptidases and / or exopeptidases of microbial or plant origin are used for this hydrolysis.
  • the collagen-containing starting material is usually selected from the skin or bones of vertebrates, preferably from mammals or birds, and in particular from the skin of cattle or pigs (cattle split or pork rind).
  • the collagen of marsupials such as kangaroos is also suitable as starting material.
  • the collagen-containing starting material may be selected from the skin, bones and / or scales of fish, in particular cold or hot water fish.
  • the collagen hydrolyzate can either be prepared from these starting materials in a one-step process or gelatin via the intermediate, in which case both Type A and Type B gelatin can be used.
  • the collagen hydrolyzate for the composition according to the invention can be produced by recombinant gene expression.
  • natural collagen sequences in particular from cattle or pigs, and their expression in genetically modified cells (eg yeasts, bacteria or plant cells, especially tobacco)
  • products can be prepared which are substantially identical to the hydrolysis products of the corresponding collagen-containing raw materials , It is possible to obtain a narrower or exactly predetermined molecular weight distribution.
  • the sequences can be altered by mutations to affect certain properties of the product.
  • An object of the present invention is also a method for improving the endurance performance and / or for stimulating the fat reduction, and in particular for reducing the body weight, by means of increasing the mitochondrial activity.
  • the method comprises administering to a human or an animal a composition comprising one or more carbohydrates and collagen hydrolyzate.
  • the method can be both a therapeutic and a non-therapeutic method.
  • Figure 1 fluorescence micrographs of SH-SY5Y cells, which were incubated in the presence of collagen hydrolyzate.
  • Figure 2 Diagram for Lactatdiagnostik in a clinical study for
  • the SH-SY5Y cells were incubated in culture media with different concentrations of collagen hydrolyzate of 0.05% by weight, 0.2% by weight and 2.5% by weight.
  • collagen hydrolyzate A a collagen hydrolyzate of pork swine gelatin having an average molecular weight in the region of 3,000 Da was used, which was prepared by enzymatic hydrolysis (referred to below as collagen hydrolyzate A).
  • the molecular weight distribution of the peptides which was determined by means of gel permeation chromatography, is given in the following Table 1:
  • TOM20 mitochondrial protein component TOM20 was fluorescently labeled.
  • TOM20 is a subunit of a receptor complex in the outer membrane of the mitochondria, which has the function of transferring cytosolic precursor proteins (prepeptides) into the mitochondria. There, the proteins, which are enzymes of the respiratory chain or of the citric acid cycle, are activated by cleavage of the presequence.
  • the amount of fluorescently labeled TOM20 visible in the fluorescence microscope is thus a measure of the mitochondrial number in the cell.
  • the cells incubated with 0.05% by weight, 0.2% by weight and 2.5% by weight of collagen hydrolyzate are shown in FIGS. 1A, 1B and 1C respectively, with an increase of the light (in the original green) with increasing concentration. Fluorescence in the areas around the nucleus (blue in the original) is clearly visible.
  • the collagen hydrolyzate thus causes an increase in the mitochondrial count in the SH-SY5Y cells, and thus an increase in the total mitochondrial activity.
  • AMP-activated protein kinase is involved in energy delivery in both adipose tissue and muscle. Since AMP is formed when consuming ATP, it can be considered as an indicator of lack of energy. The expression of AMPK thus serves to activate energy reserves from the fat depot and in the context of glycolysis.
  • AMPK RNA was significantly increased (by a factor of over 600). This finding also results in a stimulating influence of collagen hydrolyzate on the energy metabolism of the cell.
  • mice were fed daily with a quantity of collagen hydrolyzate corresponding to a human equivalence dose of 10 g over a period of 3 months. After the mice had been euthanized, the quadriceps were completely excised, snap frozen and ground. From the muscle tissue, the soluble proteins were extracted and the amount of AMPK determined by means of an immunoassay (ELISA).
  • ELISA immunoassay
  • the amount of AMPK was increased by a factor between 1.5 and 2.
  • the test group and the control group each comprised six animals.
  • a fine needle biopsy was taken from the four-headed thigh muscle (quadriceps femoris) in each rat.
  • the animals of the test groups were then given a daily dose of 200 mg of the respective collagen hydrolyzate (see below) per kg of the current body weight (corresponding to a daily dose of 15 g in a person weighing 75 kg) over a period of four weeks.
  • the collagen hydrolyzate was dissolved at a concentration of 20 mg / ml in an appropriate amount of tap water and administered via gavage.
  • the animals of the control group each received the identical amount of tap water without collagen hydrolyzate.
  • all rats received daily 25 g of feed with a carbohydrate content of 41.2% by weight, namely 36.5% by weight of high-glycemic starch and 4.7% by weight of sucrose.
  • a collagen hydrolyzate B from bovine cleavage gelatin having an average molecular weight of 2,000 Da and a collagen hydrolyzate were used in further test groups C from bovine cleavage gelatin with an average molecular weight of 3,500 Da, each produced by enzymatic hydrolysis.
  • a collagen hydrolyzate D from bovine cleavage gelatin having an average molecular weight of 12,000 Da and a collagen hydrolyzate E from fish collagen having an average molecular weight of 1,300 Da was also used, which was also enzymatically hydrolyzed.
  • the value "Cohen's d" as a measure of the effect size is more than 2.5 for all test groups, which is a very strong effect.
  • the participants in the verum group received 15 g of collagen hydrolyzate daily throughout the study period, namely the collagen hydrolyzate C described in Example 5 with an average molecular weight of 3,500 Da (see Table 2), whereas the placebo group participants instead received silica as placebo.
  • lactate diagnostics were carried out, whereby the lactate concentration in the blood was measured on a treadmill as a function of the running speed.
  • the results are shown in a diagram in FIG.
  • the measured values for the placebo group are represented by triangles and the measured values for the verum group by squares.
  • the measured values before the study period are interpolated with solid lines and the measured values after the study period with dashed lines.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Birds (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Husbandry (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une composition nutraceutique ou pharmaceutique destinée à être utilisée pour améliorer la capacité d'endurance, ainsi qu'une composition nutraceutique ou pharmaceutique destinée à être utilisée pour stimuler la réduction des graisses, en particulier pour réduire le poids corporel. Ladite composition comprend un ou plusieurs glucides et de l'hydrolysat de collagène.
PCT/EP2019/054701 2018-02-28 2019-02-26 Composition nutraceutique ou pharmaceutique WO2019166418A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102018104590.5 2018-02-28
DE102018104590.5A DE102018104590A1 (de) 2018-02-28 2018-02-28 Nutrazeutische oder pharmazeutische Zusammensetzung

Publications (1)

Publication Number Publication Date
WO2019166418A1 true WO2019166418A1 (fr) 2019-09-06

Family

ID=65686812

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2019/054701 WO2019166418A1 (fr) 2018-02-28 2019-02-26 Composition nutraceutique ou pharmaceutique

Country Status (2)

Country Link
DE (1) DE102018104590A1 (fr)
WO (1) WO2019166418A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11028148B2 (en) 2017-09-28 2021-06-08 Geltor, Inc. Recombinant collagen and elastin molecules and uses thereof
US11168126B2 (en) 2019-04-12 2021-11-09 Geltor, Inc. Recombinant elastin and production thereof
US11174300B2 (en) 2020-01-24 2021-11-16 Geltor, Inc. Animal-free dietary collagen

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102019134810A1 (de) * 2019-12-17 2021-06-17 Gelita Ag Milchersatzprodukt und Verfahren zur Herstellung

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009008714A1 (fr) * 2007-07-06 2009-01-15 Dsm Ip Assets B.V. Compositions alimentaires
US20120141448A1 (en) * 2010-11-23 2012-06-07 Lorenzo De Ferra Method for increasing muscle mass and strength
DE102011000997A1 (de) * 2011-03-01 2012-09-06 Gelita Ag Zusammensetzung für Ernährungszwecke
WO2014030514A1 (fr) * 2012-08-24 2014-02-27 国立大学法人徳島大学 Inhibiteur de l'atrophie musculaire
DE102013104897A1 (de) * 2013-05-13 2014-11-13 Gelita Ag Wirkstoff zur Behandlung von Sarkopenie
US20150104393A1 (en) * 2013-10-14 2015-04-16 Biomarker Pharmaceuticals, Inc. Nutrient combinations for affecting an aging process
DE202014105602U1 (de) * 2014-11-20 2015-11-23 RenaCare NEPHROMED GmbH Zusammensetzung zur Eiweißsubstitution
DE102014108502A1 (de) * 2014-06-17 2015-12-17 Gelita Ag Zusammensetzung in Form von kompaktierten Partikeln und deren Verwendung
WO2018041684A1 (fr) * 2016-08-30 2018-03-08 Gelita Ag Utilisation d'un hydrolysat de collagène pour améliorer la capacité d'endurance et stimuler le catabolisme lipidique

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009008714A1 (fr) * 2007-07-06 2009-01-15 Dsm Ip Assets B.V. Compositions alimentaires
US20120141448A1 (en) * 2010-11-23 2012-06-07 Lorenzo De Ferra Method for increasing muscle mass and strength
DE102011000997A1 (de) * 2011-03-01 2012-09-06 Gelita Ag Zusammensetzung für Ernährungszwecke
WO2014030514A1 (fr) * 2012-08-24 2014-02-27 国立大学法人徳島大学 Inhibiteur de l'atrophie musculaire
DE102013104897A1 (de) * 2013-05-13 2014-11-13 Gelita Ag Wirkstoff zur Behandlung von Sarkopenie
US20150104393A1 (en) * 2013-10-14 2015-04-16 Biomarker Pharmaceuticals, Inc. Nutrient combinations for affecting an aging process
DE102014108502A1 (de) * 2014-06-17 2015-12-17 Gelita Ag Zusammensetzung in Form von kompaktierten Partikeln und deren Verwendung
DE202014105602U1 (de) * 2014-11-20 2015-11-23 RenaCare NEPHROMED GmbH Zusammensetzung zur Eiweißsubstitution
WO2018041684A1 (fr) * 2016-08-30 2018-03-08 Gelita Ag Utilisation d'un hydrolysat de collagène pour améliorer la capacité d'endurance et stimuler le catabolisme lipidique

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
A. GLAUERT; P. LEWIS: "Biological Specimen Preparation for Transmission Electron Microscopy", PRINCETON LEGACY LIBRARY, 2014
A. JEUKENDRUP, SCHWEIZERISCHE ZEITSCHRIFT FÜR SPORTMEDIZIN UND SPORTTRAUMATOLOGIE, vol. 51, 2003, pages 17 - 23
ANONYMOUS: "Hydrolysed Liquid Collagen", 9 November 2015 (2015-11-09), XP055414242, Retrieved from the Internet <URL:http://naturem.co.uk/2015/11/09/hydrolysed-liquid-collagen/> [retrieved on 20171010] *
BEILO ET AL., CURR. MED. RES. OPIN., vol. 22, 2006, pages 2221 - 2232
LISKA VLADIMIR ET AL: "Evaluation of a recombinant human gelatin as a substitute for a hydrolyzed porcine gelatin in a refrigerator-stable Oka/Merck live varicella vaccine", JOURNAL OF IMMUNE BASED THERAPIES AND VACCINES, BIOMED CENTRAL LTD., LONDON, GB, vol. 5, no. 1, 23 February 2007 (2007-02-23), pages 4, XP021024500, ISSN: 1476-8518, DOI: 10.1186/1476-8518-5-4 *
PETZKE K J ET AL: "THE INFLUENCE OF HIGH GLYCINE DIETS ON THE ACTIVITY OF GLYCINE-CATABOLIZING ENZYMES AND ON GLYCINE CATABOLISM IN RATS", THE JOURNAL OF NUTRITION, AMERICAN SOCIETY FOR NUTRITION, US, vol. 116, no. 5, 1 January 1986 (1986-01-01), pages 742 - 750, XP009500684, ISSN: 0022-3166, DOI: 10.1093/JN/116.5.742 *
PIECZENIK ET AL: "Mitochondrial dysfunction and molecular pathways of disease", EXPERIMENTAL AND MOLECULAR PATHOLOGY, ACADEMIC PRESS, US, vol. 83, no. 1, 2 June 2007 (2007-06-02), pages 84 - 92, XP022103261, ISSN: 0014-4800, DOI: 10.1016/J.YEXMP.2006.09.008 *
RUOCHEN CHE ET AL: "Mitochondrial dysfunction in the pathophysiology of renal diseases", AMERICAN JOURNAL OF PHYSIOLOGY: RENAL PHYSIOLOGY, vol. 306, no. 4, 15 February 2014 (2014-02-15), United States, pages F367 - F378, XP055590807, ISSN: 1931-857X, DOI: 10.1152/ajprenal.00571.2013 *
STEPHEN E. ALWAY ET AL: "Mitochondria Initiate and Regulate Sarcopenia :", EXERCISE AND SPORT SCIENCES REVIEWS, vol. 45, no. 2, 1 April 2017 (2017-04-01), US, pages 58 - 69, XP055590536, ISSN: 0091-6331, DOI: 10.1249/JES.0000000000000101 *
T OKIURA ET AL: "Effects of collagen hydrolysate on the tibialis anterior muscle and femur in senescence-accelerated mouse prone 6", JOURNAL OF MUSCULOSKELETAL & NEURONAL INTERACTIONS, 1 January 2016 (2016-01-01), Greece, pages 161, XP055414203, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5114359/pdf/JMNI-16-161.pdf> [retrieved on 20190603] *
WILLIAM I. SIVITZ ET AL: "Mitochondrial Dysfunction in Diabetes: From Molecular Mechanisms to Functional Significance and Therapeutic Opportunities", ANTIOXIDANTS AND REDOX SIGNALING, vol. 12, no. 4, 15 February 2010 (2010-02-15), US, pages 537 - 577, XP055590803, ISSN: 1523-0864, DOI: 10.1089/ars.2009.2531 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11028148B2 (en) 2017-09-28 2021-06-08 Geltor, Inc. Recombinant collagen and elastin molecules and uses thereof
US11041015B2 (en) 2017-09-28 2021-06-22 Geltor, Inc. Recombinant collagen and elastin molecules and uses thereof
US11180541B2 (en) 2017-09-28 2021-11-23 Geltor, Inc. Recombinant collagen and elastin molecules and uses thereof
US11214609B2 (en) 2017-09-28 2022-01-04 Geltor, Inc. Recombinant collagen and elastin molecules and uses thereof
US11168126B2 (en) 2019-04-12 2021-11-09 Geltor, Inc. Recombinant elastin and production thereof
US11174300B2 (en) 2020-01-24 2021-11-16 Geltor, Inc. Animal-free dietary collagen
US11332505B2 (en) 2020-01-24 2022-05-17 Geltor, Inc. Animal-free dietary collagen

Also Published As

Publication number Publication date
DE102018104590A1 (de) 2019-08-29

Similar Documents

Publication Publication Date Title
WO2018041684A1 (fr) Utilisation d&#39;un hydrolysat de collagène pour améliorer la capacité d&#39;endurance et stimuler le catabolisme lipidique
WO2019166418A1 (fr) Composition nutraceutique ou pharmaceutique
DE60119891T2 (de) Zusammensetzung zur verminderung geistiger ermüdung
DE502007010071C5 (de) Verwendung einer zusammensetzung aus mineralstoffen und gegebenenfalls acetogenen und/oder butyrogenen bakterien zur vermeidung oder reduzierung von gasbildung im dickdarm eines säugetiers und dadurch bedingter abdominaler beschwerden
DE60024438T2 (de) Sportlergetränk mit Spurenelementen und lebensfähigen Lactobazillen
DE102008036954B4 (de) Verwendung einer Aminozucker enthaltenden Zusammensetzung
DE19528461A1 (de) Präparat zur Ernährung
DE102009016119A1 (de) Nahrungsergänzungsmittel enthaltend alpha-Ketosäuren zur Unterstützung der Diabetestherapie
EP0874618A1 (fr) Preparation pour stimuler la pousse des cheveux, ameliorer la structure de la peau et/ou regenerer les ongles
DE60104853T2 (de) Zusammensetzungen umfassend Folsäure und Zink zum Verbessern der Samenqualität
DE69633818T2 (de) Verwendung eines mittels zur zur vorbeugung oder behandlung von durch anomalitäten des knorpelgewebes verursachten erkrankungen
WO2008138821A1 (fr) Composition à base de matière grasse lactique et de protéine lactique (de préférence, estérifiée par l&#39;acide palmitique) destinée à l&#39;amélioration de l&#39;absorption du calcium
AT513274B1 (de) Nahrungsergänzungsmittel
DE60032509T2 (de) Chrom-histidin-komplexe als nahrungsmittelzusätze
DE102007053369A1 (de) Verwendung einer eine Kreatin-Komponente enthaltende Zusammensetzung zur Verbesserung der männlichen Fruchtbarkeit
DE69928826T2 (de) Zubereitungen für die behandlung und verhinderung von kardiovaskulären erkrankungen
AT510810B1 (de) Kombinationspräparat zur verbesserung der weiblichen fertilität
EP2996710B1 (fr) Substance active pour le traitement de la sarcopénie
US20220105158A1 (en) Use of collagen hydrolysate for improving endurance performance and for stimulating lipid catabolism
WO2020182831A1 (fr) Complément alimentaire
DE69936056T2 (de) Nahrungsmittelergänzung, welche liponsäure und kreatin enthält und methoden zu deren anwendung
DE60037197T2 (de) Verwendung funktioneller oraler präparate
AT412381B (de) Kombinations-präparat, enthaltend mineralstoffe, vitamine, kohlenhydrate und aminosäuren
DE19830768A1 (de) Kreatin-enthaltende Formulierung und Verfahren zu deren Herstellung
DE10352822A1 (de) Verwendung einer zusätzlich fermentierten Getreideschlempe zur Vorbeugung und/oder Behandlung erhöhter Blutzucker-Werte

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19709391

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 19709391

Country of ref document: EP

Kind code of ref document: A1